Speaker Name: Dr. Janaka Karalliedde, Professor of Diabetes, Kings College, London, UK.

Explore this session to:

• Recognize early cardiometabolic risk driven by visceral adiposity leading to insulin resistance and endothelial dysfunction at lower BMI.
• Understand the AHA CKM framework for early identification of interconnected cardiometabolic and renal dysfunction.
• Apply KDIGO-recommended screening using uACR and eGFR, with early HF evaluation guided by ESC and NICE guideline recommendations.
• Interpret the link between albuminuria, declining kidney function, and increasing HF risk for timely diagnosis.
• Evaluate findings from EMPA-REG OUTCOME and SELECT, and apply ADA and IDF guideline-directed therapy, including SGLT2i, GLP-1 RA, RAS blockers, and non-steroidal MRAs for CKM risk reduction.